Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
The glucagon-like peptide 1 (GLP-1) drugs is a class that includes now-famous Ozempic (semaglutide) and Mounjaro (tirzepatide), which were approved by the FDA as diabetes treatments but have been used off-label for weight loss. After FDA approvals, on-label versions are available for weight, marketed under the names Wegovy (semaglutide) and Zepbound (tirzepatide). Prescriptions of the GLP-1s have soared as patients and prescribers have flocked to a pharmaceutical answer to the U.S. obesity epidemic. The cost has strained insurer budgets. There are also questions about the long-term outcomes of GLP-1s and how long people are sticking with the treatments, which are administered as injections.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.
Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss
We want to know what you’re thinking! Every Monday morning the editors of Managed Healthcare Executive are posing a question to our readers about a timely issue in U.S. healthcare. Answers will be published every Friday.
FDA Updates for the Week of May 6: An Approval, a Delay and Two Ad Comm Meetings
May 11th 2024The FDA has approved a liquid mycophenolate to prevent organ rejections but delayed the approval of Moderna’s RSV vaccine. Regulators have set dates for advisory committee meetings for midomafetamine for PTSD and for donanemab in Alzheimer’s disease. Additionally, the agency has set review dates for a subcutaneous Opdivo and a pancreatic/lung cancer therapy.
Read More